Background: Familial intestinal gastric cancer (FIGC) remains genetically unexplained and without testing/clinical criteria. Herein, we characterised the age of onset and disease spectrum of 50 FIGC families and searched for genetic causes potentially underlying a monogenic or an oligogenic/polygenic inheritance pattern. Methods: Normal and tumour DNA from 50 FIGC probands were sequenced using Illumina custom panels on MiSeq, and their respective germline and somatic landscapes were compared with corresponding landscapes from sporadic intestinal gastric cancer (SIGC) and hereditary diffuse gastric cancer cohorts. Results: The most prevalent phenotype in FIGC families was gastric cancer, detected in 138 of 208 patients (50 intestinal gastric cancer probands and 88 unknown gastric cancer histology relatives), followed by colorectal and breast cancers. After excluding benign and intronic variants lacking impact in splicing, 12 rare high-quality variants were found exclusively in 11 FIGC probands. Only two probands carried potentially deleterious variants, but lacked somatic second-hits, weakly supporting the monogenic hypothesis for FIGC. However, FIGC probands developed gastric cancer at least 10 years earlier and carried more TP53 germline common variants than SIGC (p=4.5E-03); FIGC and SIGC could be distinguished by specific germline and somatic variant profiles; there was an excess of FIGC tumours presenting microsatellite instability (38%); and FIGC tumours displayed significantly more somatic common variants than SIGC tumours (p=4.2E-06). Conclusion: This study proposed the first data-driven testing criteria for FIGC families, and supported FIGC as a genetically determined, likely polygenic, gastric cancer-predisposing disease, with earlier onset and distinct from patients with SIGC at the germline and somatic levels.

Redefinition of familial intestinal gastric cancer: Clinical and genetic perspectives / J. Carvalho, P.O.. - In: JOURNAL OF MEDICAL GENETICS. - ISSN 0022-2593. - 58:1(2020 Jan), pp. 106346.1-106346.11. [10.1136/jmedgenet-2019-106346]

Redefinition of familial intestinal gastric cancer: Clinical and genetic perspectives

G. Corso;
2020

Abstract

Background: Familial intestinal gastric cancer (FIGC) remains genetically unexplained and without testing/clinical criteria. Herein, we characterised the age of onset and disease spectrum of 50 FIGC families and searched for genetic causes potentially underlying a monogenic or an oligogenic/polygenic inheritance pattern. Methods: Normal and tumour DNA from 50 FIGC probands were sequenced using Illumina custom panels on MiSeq, and their respective germline and somatic landscapes were compared with corresponding landscapes from sporadic intestinal gastric cancer (SIGC) and hereditary diffuse gastric cancer cohorts. Results: The most prevalent phenotype in FIGC families was gastric cancer, detected in 138 of 208 patients (50 intestinal gastric cancer probands and 88 unknown gastric cancer histology relatives), followed by colorectal and breast cancers. After excluding benign and intronic variants lacking impact in splicing, 12 rare high-quality variants were found exclusively in 11 FIGC probands. Only two probands carried potentially deleterious variants, but lacked somatic second-hits, weakly supporting the monogenic hypothesis for FIGC. However, FIGC probands developed gastric cancer at least 10 years earlier and carried more TP53 germline common variants than SIGC (p=4.5E-03); FIGC and SIGC could be distinguished by specific germline and somatic variant profiles; there was an excess of FIGC tumours presenting microsatellite instability (38%); and FIGC tumours displayed significantly more somatic common variants than SIGC tumours (p=4.2E-06). Conclusion: This study proposed the first data-driven testing criteria for FIGC families, and supported FIGC as a genetically determined, likely polygenic, gastric cancer-predisposing disease, with earlier onset and distinct from patients with SIGC at the germline and somatic levels.
cancer; Gastric; clinical genetics; diagnostics; evidence based practice; molecular genetics
Settore MED/18 - Chirurgia Generale
Settore MEDS-06/A - Chirurgia generale
   STUDY OF SECRETED CELL VESICLES DURING EPITHELIAL-MESENCHYMAL-EPITHELIAL TRANSITIONS AND THEIR ROLE IN THE CANCER METASTATIC PROCESS - Circulating Exosomes: a tool to follow gastric tumour dynamics and therapy response
   Fundação para a Ciência e a Tecnologia, I.P.
   null
   SFRH/BPD/86543/2012

   ALL TOGETHER NOW: COMBINED INFLUENCE OF E-CADHERIN MODULATORS IN EPITHELIAL-MESENCHYMAL-EPITHELIAL TRANSITIONS AND CANCER PROGRESSION
   Fundação para a Ciência e a Tecnologia, I.P.
   null
   SFRH/BPD/89764/2012

   CDH1 LOCUS, THE NEXT JEKYLL AND HYDE IN CANCER?
   Fundação para a Ciência e a Tecnologia, I.P.
   null
   SFRH/BPD/79499/2011

   Unveil CDH1 regulatory network, beyond coding mutations in HDGC
   Fundação para a Ciência e a Tecnologia, I.P.
   null
   SFRH/BD/140796/2018
gen-2020
17-feb-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
1.full.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Licenza: Nessuna licenza
Dimensione 2.4 MB
Formato Adobe PDF
2.4 MB Adobe PDF [it] Default value:   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I metadati presenti in AIR sono rilasciati con licenza CCO mentre i file delle pubblicazioni sono rilasciati con licenza CC BY-SA, salvo diversa indicazione. In caso di violazione di copyright, contattare l'assistenza di AIR

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/737680
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 31
  • OpenAlex 45
social impact